"Does PD-1 blockade play a decisive role in the pathological complete remission of unresectable MSS, BRAF V600E-mutated metastatic colorectal cancer: A case report"

作者全名："Tan, Li; Li, Qing-Shu; Peng, Dong; Cheng, Yong"

作者地址："[Tan, Li; Peng, Dong; Cheng, Yong] Chongqing Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Chongqing, Peoples R China; [Li, Qing-Shu] Chongqing Med Univ, Sch Basic Med, Dept Pathol, Chongqing, Peoples R China"

通信作者："Peng, D; Cheng, Y (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Chongqing, Peoples R China."

来源：FRONTIERS IN ONCOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000918530800001

JCR分区：Q2

影响因子：4.7

年份：2023

卷号：12

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：colorectal cancer (CRC); programmed death-1 inhibitor (PD-1 inhibitor); immunotherapy; targeted therapy; microsatellite-stable (MSS); case report

摘要："BackgroundColorectal cancer (CRC) ranks third in highest incidence among human cancers. With the continuous development of anti-cancer drugs, CRC patients are treated more and more effectively. However, the treatment of patients with unresectable metastatic CRC (mCRC) remains a core point for surgeons worldwide, especially for those with microsatellite stability (MSS) and BRAF V600E mutation, who have been reported to have the worst prognosis. Case descriptionWe report a case of pathological complete remission in a patient with unresectable MSS, BRAF V600E-mutated metastatic rectal cancer after using Vemurafenib and Cetuximab in combination with Camrelizumab. ConclusionsThis case suggested that Vemurafenib and Cetuximab combined with Camrelizumab is effective in the treatment of MSS, BRAF V600E-mutated mCRC. To benefit more patients, further studies need to be completed."

基金机构：　

基金资助正文：